Bull of the Day: Lannett (LCI)

Lannett Company, Inc. ( LCI ) is cashing in on the demand for generic drugs. This Zacks Rank #1 (Strong Buy) just announced a huge acquisition which will be accretive to earnings nearly immediately.

Lannett, with a $2 billion market cap, makes thyroid, cardiovascular and pain management generic drugs. Acquisition of Kremers Urban Pharmaceuticals Will Diversify Its Business On Sep 2, Lannett announced it was acquiring Kremers Urban Pharmaceuticals, an American specialty generic subsidiary of UCB S.A. for $1.23 billion in cash and loans. This is a game changing acquisition for the company as it basically boosts its market cap by 50% in a single deal. It also diversifies its product line. Kremers drugs treat a bunch of different conditions including ADHD, gastroesophageal reflux disease, hypertension and respiratory disease. This will give Lannett a whole new template from which to operate. The company said the deal will be accretive to fiscal 2016 in the mid-to-high single digits and 20% to 25% to EPS in fiscal 2017. Estimates Jump Analysts immediately raised estimates to reflect the Kremers deal, which isn't expected to close until the fourth quarter of calendar 2015. Fiscal 2016's Zacks Consensus Estimate jumped to $3.95 from $3.81 in the last week. Fiscal 2017's Zacks Consensus Estimate rose to $4.72 from $4.14 in the last 7 days, which is earnings growth of 19.5% over this year. Solid Fundamentals With all the recent M&A activity, there aren't many mid-cap generic drug makers left out there. Lannett shares jumped on the Kremers acquisition news, but they're still trading well below their 2015 highs.

Shares are still very attractively priced. Lannett trades with a forward P/E of just 14 which is under the average of the S&P 500 of 16.7. For investors looking for a cheap generic drug play, Lannett should be on the short list. Want More of Our Best Recommendations? Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential . Learn More>>Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec .

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.